Most people treated for endometrial cancer will not experience a recurrence, but understanding the risk and follow-up plan can help patients stay informed and prepared. According to a 2024 study published in Frontiers in Oncology, endometrial cancer returns in roughly 15% to 20% of patients overall. However, those numbers vary widely based on individual factors.
Assessing Recurrence Risk
Dr. Josephine Kim, a gynecologic oncologist at City of Hope Orange County, explained that personal risk depends on the cancer’s stage, aggressiveness, molecular subtype, and treatment received. A low-grade cancer confined to the uterus generally carries a much lower risk than a high-grade cancer or one that has spread. Most recurrences occur within two to three years after treatment, which is why follow-up visits are scheduled more frequently during that time.
Molecular testing has become a key tool in refining recurrence estimates. Dr. James Hamrick, an oncologist and chairman of the Caris Life Sciences Precision Oncology Alliance, outlined how each of the four molecular subtypes influences prognosis. Tumors with POLE mutations typically have an excellent prognosis and very low recurrence risk, particularly in early-stage disease. MMR-deficient tumors show intermediate risk but may respond especially well to immunotherapy. p53-abnormal cancers tend to behave more aggressively and carry a higher risk of recurrence, potentially affecting post-surgery treatment decisions. The NSMP subtype is more varied, with lower-grade, hormone receptor-positive tumors often having better outcomes.
Dr. Hamrick emphasized that while molecular subtypes provide valuable insight, they cannot predict outcomes with certainty for any individual patient. “A molecular subtype helps us understand risk; it cannot tell us with certainty what will happen to an individual person,” he said. Care teams integrate these results with cancer stage, pathology, and prior treatments to tailor follow-up and, if needed, adjuvant therapy plans.
Follow-Up and Symptom Monitoring
The American Cancer Society recommends physical exams every three to six months for the first two to three years after treatment, followed by visits every six to twelve months for up to five years. Routine blood tests or imaging are not advised for asymptomatic patients with normal exams. Instead, scans are ordered based on symptoms or physical findings. Patients should promptly report warning signs such as new vaginal bleeding or spotting, persistent pelvic or abdominal pain, unexplained weight loss, or a lingering cough and shortness of breath.
Related Post: New dual-imaging catheter assesses heart attack risk in humans
If recurrence occurs, the most common sites include the vaginal cuff, pelvis, lymph nodes, and abdomen, with the lungs being a frequent location for distant spread. Where the cancer returns plays a major role in determining treatment goals. A recurrence limited to the vagina, for example, may still be treatable with curative intent, especially if radiation was not previously administered to that area. Dr. Kim noted that early reporting of symptoms can improve outcomes, particularly when localized treatment remains an option.
When cancer does return, treatment decisions begin with assessing the location and extent of recurrence, the amount of cancer present, and prior therapies used. For localized or regional recurrence, radiation or surgery may be considered with curative intent. In cases of distant disease, treatment typically shifts to systemic therapies. Chemotherapy combined with immunotherapy has emerged as a common approach, and hormone therapy or targeted treatments may be appropriate depending on tumor characteristics. Clinical trials are also encouraged as part of the treatment discussion for eligible patients.
Newer Immunotherapy Options
Recent FDA approvals have expanded treatment options for patients with advanced or recurrent endometrial cancer. In 2023, Jemperli (dostarlimab) combined with chemotherapy received approval for primary advanced or recurrent MMR-deficient or microsatellite instability-high (MSI-high) endometrial cancer. The following year, the FDA broadened this indication to include all adult patients with primary advanced or recurrent disease.
Also in 2024, Keytruda (pembrolizumab) plus chemotherapy gained FDA approval for primary advanced or recurrent endometrial cancer. Imfinzi (durvalumab) plus chemotherapy was approved for MMR-deficient disease that has progressed following other treatments, as reported by the National Cancer Institute. These approvals reflect growing reliance on molecular profiling to guide therapeutic choices in recurrent settings.
Coping with the Fear of Recurrence
Fear of recurrence remains one of the most common concerns among survivors, and Dr. Hamrick acknowledged that such anxiety is both normal and understandable. He emphasized that finishing treatment does not instantly eliminate worry, noting that routine physical sensations can take on heightened significance after a cancer diagnosis.